Petronas subsidiaries mixed in early session amid workforce cut announcement
The national oil company announced yesterday that the move will help to cope with challenging operating conditions, particularly due to falling crude prices.
As at 10.24 am, MISC was flat at RM7.60, Petronas Dagangan was 10 sen lower at RM21.04, Petronas Chemicals Group decreased 6.0 sen to RM3.30, and Petronas Gas was flat at RM18.18.
According to reports on Thursday, Petronas president/group chief executive officer Tan Sri Tengku Muhammad Taufik Tengku Aziz said the number of staff involved in the right-sizing process currently stands at around 5,000. Those affected will be notified in stages next year.
Petronas has based its budget on Brent crude trading between US$75 and US$80 per barrel.
The benchmark is currently near US$65, down roughly 13 per cent this year, amid global trade tensions and rising OPEC+ output.
The group reported a net profit of RM55.1 billion for the financial year ended Dec 31, 2024, down 31.7 per cent from RM80.7 billion a year earlier, due to lower average realised prices and favourable tax adjustments in 2023.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
31 minutes ago
- Malaysian Reserve
Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031
NEW YORK, July 18, 2025 /PRNewswire/ — According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing significantly with the increasing prevalence of ocular diseases. The global preservative-free eye drops market is expected to reach US$1.67 billion in 2031 from US$1.21 billion in 2024. The market is estimated to grow at a CAGR of 4.3% from 2025 to 2031. The increasing prevalence of ocular diseases, the aging global population, surging awareness for chemical-free products, and supportive regulations and recommendations fuel market growth. However, limited availability of such products in the market and shorter shelf life hinder market growth. To explore the valuable insights in the Preservative Free Eye Drops Market report, you can easily download a sample PDF of the report – The preservative-free eye drops market is segmented on the basis of type, application, and distribution channel. The report runs an in-depth analysis of market trends, key players, and future opportunities. Overview of Report Findings Increasing Prevalence of Ocular Diseases: Age-related complications such as cataracts, glaucoma, and macular degeneration are among the top causes of vision loss globally. As per the report 'Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment' published in 2022, age-related macular degeneration impacts over 200 million people worldwide and is expected to reach 300 million by 2040. As per the WHO 2023, in Europe, approximately 90 million people have some form of vision impairment or blindness, representing ~9% of the population. The prevalence of these complications highlights the need for efficient eye care treatment. Preservative-free eye drops provide a safer option for people suffering from chronic eye diseases, reducing the risk of preservative-related irritation and toxicity. Rising Aging Population: With age, individuals become more prone to dry eye syndrome, glaucoma, age-related macular degeneration, and cataracts. These disorders need to be treated long-term or even for a lifetime through ophthalmic solutions. But conventional preservative-containing eye drops such as those containing benzalkonium chloride (BAK), are known to induce or worsen irritation, inflammation, and injury to the ocular surface, particularly with prolonged use. Elderly patients are susceptible to such side effects because of thinner tear films and lower regenerative capacity of the ocular surface. Preservative-free eye drops, which provide a milder and safer option, are increasingly being favored among this population. The tendency is particularly prominent in industrialized nations with an accelerating aging population, including Japan, Germany, and the US. It is also gaining prominence in China and India. Clinicians today are inclined to prescribe preservative-free drugs for older patients with chronic diseases. With the world population aged 60 and above expected to double by the year 2050, demand for safer, better-tolerated ophthalmic products will surge, driving market growth. For Detailed Preservative Free Eye Drops Market Insights, Visit: Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific. Asia Pacific is expected to register the highest CAGR in the preservative free eye drops market during the forecast period. Market Segmentation By type, the preservative free eye drops market is segmented into single dose and multiple dose. The single-dose segment held a larger share of the market in 2024, and it is anticipated to register the highest CAGR in the market during 2025–2031. Based on application, the preservative free eye drops market has been segmented into dry eye disease (DED), eye allergy/ infection, glaucoma, retinal disorders, and other indications. The dry eye disease segment held the largest share of the market in 2024 and is expected to register a higher CAGR in the market during 2025–2031. In terms of distribution channel, the preservative free eye drops market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2024. The online pharmacies segment is expected to register the highest CAGR in the market during 2025–2031. The preservative free eye drops market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. Stay Updated on The Latest Preservative Free Eye Drops Market Trends: Competitive Strategy and Development Key Players: Major companies operating in the preservative free eye drops market are Nemera, Alcon Inc., Bausch & Lomb Incorporated, Eyekare Kilitch Ltd., Essex Bio-Technology Limited, Pillar5 Pharma Inc., iVIZIA, Allergan PLC, CorneaCare Inc. Trending Topics: Dry Eye Disease (DED) Treatment, Glaucoma Therapeutics, Allergic Conjunctivitis Treatment, Contact Lens Care Products, Ophthalmic Surgical Products, Natural and Organic Eye Care Products, Pediatric Eye Care, etc. Global Headlines on Preservative Free Eye Drops Market Lumify Preservative Free Redness-Reducing Eye Drops Launch in US Alcon Announces US Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Long-Lasting Formula Purchase Premium Copy of Global Preservative Free Eye Drops Market Size and Growth Report (2021-2031) at: Conclusion The preservative free eye drops market is growing, driven primarily by the rising prevalence of chronic ocular diseases, an aging global population, and increasing consumer awareness of the adverse effects associated with preservatives. Advances in sterile packaging technologies have made preservative-free formulations more accessible and convenient. Additionally, soaring demand for safer, natural, and more tolerable eye care products aligns with broader healthcare and lifestyle trends. However, higher production costs and limited availability in certain regions limit growth. Overall, the market's future looks promising as healthcare providers and consumers prioritize ocular safety and comfort, making preservative-free eye drops a vital segment in the evolving ophthalmic therapeutics landscape. The report from The Insight Partners lists several stakeholders—including manufacturers, healthcare providers, distributors and suppliers, and regulatory bodies—along with valuable insights on how to successfully navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: The Allergy Relieving Eye Drops Market Size is expected to register a CAGR of 4.2% from 2025 to 2031 Eye Drops and Lubricants Market Size, Trends, Shares, and Forecast – 2031 Dry Eye Disease Market Size is expected to register a CAGR of 5.6% from 2025 to 2031 Diabetic Eye Disease Equipment Market Size, Trends, Shares, and Forecast – 2031 Dry Eye Disease Diagnostic Devices Market Size, Trends, Shares, and Forecast – 2031 The eye allergy treatment market size is projected to reach US$ 5.69 billion by 2030 Retinal Surgery Devices Market Size is expected to register a CAGR of 5.9% from 2025 to 2031 Retinal Implant Market Size is expected to register a CAGR of 8.4% from 2025 to 2031 The Thyroid Eye Disease Treatment Market Size is expected to register a CAGR of 6.3% from 2025 to 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us:If you have any queries about this report or if you would like further information, please contact us:Contact Person: Ankit MathurE-mail: +1-646-491-9876Press Release – More Life Sciences Research Reports & Industry Analysis – Logo: View original content:
Malaysiakini
3 hours ago
- Malaysiakini
TH Plantations CEO on garden leave, CFO resigns over RM5m payouts
TH Plantations Bhd (THP) CEO Mohamed Zainurin Mohamed Zain and CFO Marliyana Omar have been served with show cause letters, relating to alleged unauthorised payments of RM5.1 million made to plantation workers. Zainurin has also been placed on garden leave commencing from the date of issuance of the show cause letter until further notice, the group said in a filing with Bursa Malaysia today.
Free Malaysia Today
3 hours ago
- Free Malaysia Today
Wall Street futures edge up as optimism over economy offsets Netflix's fall
The S&P 500 and the Dow are on track for only modest advances this week, as investors navigate a swirl of mixed signals. (AP pic) NEW YORK : US stock index futures inched higher today, buoyed by signs of a resilient US economy, even as Netflix's market-beating quarterly profit failed to dazzle investors. At 5.30am, S&P 500 E-minis were up 8.75 points, or 0.14%, Nasdaq 100 E-minis were up 33 points, or 0.14%, and Dow E-minis were up 66 points, or 0.15%. Wall Street's winning streak continued overnight, with the S&P 500 and the Nasdaq notching fresh record closes after upbeat data on retail sales and jobless claims signaled a healthy US economy. The data gives the Federal Reserve (Fed) some breathing room to assess the inflationary effects of US tariffs. Netflix rode the success of 'Squid Game' to top earnings estimates and boost its revenue outlook for the year. Yet, the streaming giant's shares slipped 1.5% in premarket trading. It has risen 43% this year. All eyes remain on whether President Donald Trump's tariff measures are starting to ripple through the economy. The Fed has signaled it will stay the course on interest rates until it sees clearer signs of how higher import taxes are shaping inflation. Traders now put the odds of a rate cut in September at about 56.3%, with a July move nearly off the table, according to CME's FedWatch tool. 'This week's data supports the wait-and-see camp on the Fed. 'Tariffs are percolating to consumer prices but is not withholding households from opening their wallets,' said Kenneth Broux, head of corporate research and rates, at Societe Generale. Fed governor Christopher Waller signaled yesterday that mounting economic risks and tame inflation have him backing an interest rate cut by this month's end, downplaying concerns that tariffs will fuel lasting price hikes. As the second-quarter earnings season gets underway, early results from 36 S&P 500 companies that reported, more than 80% have topped Wall Street's earnings expectations, according to LSEG I/B/E/S data. The S&P 500 and the Dow are on track for only modest advances this week, as investors navigate a swirl of mixed signals – robust retail sales, a spike in consumer inflation, and a stall in producer prices for June. Cryptocurrency stocks rose after the US House of Representatives passed a bill that would develop a regulatory framework for cryptocurrencies. Robinhood Markets and Coinbase Global gained 1.9% each, while Bitfarms rose 2.8% and Hut 8 advanced 1.3%.
